Clinical trial NCT05043324: Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
Official title: Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Covid19
Keywords: AIDS
HIV
HBV
HCV
Stroke
Metabolic dissorder
Stress
Lead sponsor: Trieu, Nguyen Thi, M.D.
Sponsor class: INDIV
First posted: 2021-09-14
Enrollment: 82
Sex: ALL
Minimum age (years): 16
Maximum age (years): 82
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Detailed description: AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body.

AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before.

AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ...

The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation.

AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations.

AntiCov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health.

AntiCov-220 can be used alongside with current standard treatment regimens prescribed by the World Health Organization.

Eligibility criteria: Inclusion Criteria:

* All patients with underlying medical conditions who have been taking medications for these conditions.
* Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
* The cancer patients are stable.
* Patients with congenital or acquired immunodeficiency.

Exclusion Criteria:

* Unstable cancer patients.

Primary outcomes:
measure: Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1)
timeFrame: - 18 months
Secondary outcomes:
measure: Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2)
timeFrame: - 18 months
Other outcomes:
Locations:
city: Wilmington
country: United States
facility: Saigon Biopharma LLC
state: Delaware
city: Ho Chi Minh City
country: Vietnam
facility: Saigon Biopharma Company Limited
Study officials:
affiliation: Saigon Biopharma Company Limited
name: Tran Minh Cam Tu, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi MR, Akhondzadeh S. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial? Clin Neuropharmacol. 2020 Sep/Oct;43(5):139-145. doi: 10.1097/WNF.0000000000000405.
citation: Roth A, Schaffner W, Hertel C. Phytoestrogen kaempferol (3,4',5,7-tetrahydroxyflavone) protects PC12 and T47D cells from beta-amyloid-induced toxicity. J Neurosci Res. 1999 Aug 1;57(3):399-404.
citation: Naran K, Nundalall T, Chetty S, Barth S. Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol. 2018 Dec 21;9:3158. doi: 10.3389/fmicb.2018.03158. eCollection 2018.
citation: Natural Products Structural Diversity-I Secondary Metabolites: Organization and Biosynthesis
citation: Herbal Support for Adrenal Function BY JAMES ROUSE, N.D.
citation: Majewski M. Allium sativum: facts and myths regarding human health. Rocz Panstw Zakl Hig. 2014;65(1):1-8.
citation: Krest I, Keusgen M. Stabilization and pharmaceutical use of alliinase. Pharmazie. 1999 Apr;54(4):289-93.
citation: Ullah A, Munir S, Badshah SL, Khan N, Ghani L, Poulson BG, Emwas AH, Jaremko M. Important Flavonoids and Their Role as a Therapeutic Agent. Molecules. 2020 Nov 11;25(22):5243. doi: 10.3390/molecules25225243.
citation: Clinical characteristics, multi-organ dysfunction, and outcomes of patients with COVID-19: A prospective observational study
citation: Lessel D, Kubisch C. Hereditary Syndromes with Signs of Premature Aging. Dtsch Arztebl Int. 2019 Jul 22;116(29-30):489-496. doi: 10.3238/arztebl.2019.0489.
citation: Jones QR, Warford J, Rupasinghe HP, Robertson GS. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci. 2012 Nov;33(11):602-10. doi: 10.1016/j.tips.2012.08.002. Epub 2012 Sep 12.
citation: Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007 Apr 9;167(7):635-41. doi: 10.1001/archinte.167.7.635.
citation: Abdullah M, Jamil RT, Attia FN. Vitamin C (Ascorbic Acid). 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK499877/
citation: van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, Bos GMJ. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients. 2019 Apr 28;11(5):977. doi: 10.3390/nu11050977.
citation: van Gorkom GNY, Klein Wolterink RGJ, Van Elssen CHMJ, Wieten L, Germeraad WTV, Bos GMJ. Influence of Vitamin C on Lymphocytes: An Overview. Antioxidants (Basel). 2018 Mar 10;7(3):41. doi: 10.3390/antiox7030041.